Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Delivers Bioinformatics Platform to Plough

Premium

WALTHAM, Mass.--Genome Therapeutics here has delivered a customized bioinformatics platform to Schering-Plough as part of a research alliance between the two companies aimed at discovering antiinfective agents that are effective against drug-resistant bacteria. The delivery triggered a milestone payment to Genome Therapeutics of an undisclosed sum.

Two years ago, the firms entered into a multiyear alliance worth $43.5 million. The payment for delivering the bioinformatics platform was the drug company's fifth milestone installment. Previous payments, totaling about $11 million, were for such events as delivering a sequence for the Staphylococcus aureus bacteria and providing multiple assays for validated targets. The delivery of PathoGenome, Genome Therapeu tics' microbial and fungal sequence database, to Schering-Plough, is the first bioinformatics transfer between the two firms, a Genome Therapeutics spokesman said.

PathoGenome was released in May and is also used by Bayer AG and Bristol-Myers Squibb. The proprietary bioinformatics platform combines detailed genetic and biological information in a way that lets researchers analyze and compare genomic information to identify potential drug targets.

Filed under

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.